Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 10/2015

01-10-2015 | Hypertension and the Brain (S Stocker, Section Editor)

Antihypertensive Therapies and Cognitive Function: a Review

Authors: Nisharahmed Kherada, Todd Heimowitz, Clive Rosendorff

Published in: Current Hypertension Reports | Issue 10/2015

Login to get access

Abstract

Increasing life expectancy has made old age-related health problems like dementia and cognitive decline more prevalent, and these are rapidly becoming important causes of disability and poor quality of life, causing significant add-ons to health-care costs worldwide. Hypertension is the most important modifiable vascular risk factor for the development and progression of both cognitive decline and dementia. In many observational and randomized studies, antihypertensive therapies have been shown to be beneficial in slowing cognitive decline. However, due to observed discrepancies by these studies, there is a lack of consensus on the best antihypertensive strategy for the prevention or slowing of cognitive decline. It is also not clear whether the beneficial effect of antihypertensive therapy is due to the use of a specific class of agents or combination therapy. Thus, we present a comprehensive review of overall antihypertensive therapies and cognition and of the individual antihypertensive therapy classes with their specific protective mechanisms and available clinical evidence behind their effect on cognitive function.
Literature
1.
Rosendorff C, Beeri MS, Silverman JM. Cardiovascular risk factors for Alzheimer’s disease. Am J Geriatr Cardiol. 2007;16(3):143–9.CrossRefPubMed
2.•
Gasecki D et al. Hypertension, brain damage and cognitive decline. Curr Hypertens Rep. 2013;15(6):547–58. A review discussing the link between HTN brain functional and structural changes, and to cognitive decline and dementia and the role of antihypertensive therapies in prevention of cognitive decline.PubMedCentralCrossRefPubMed
3.
Wimo A et al. The worldwide economic impact of dementia 2010. Alzheimers Dement. 2013;9(1):1–11. e3.CrossRefPubMed
4.
Frishman WH. Are antihypertensive agents protective against dementia? a review of clinical and preclinical data. Heart Dis. 2002;4(6):380–6.CrossRefPubMed
5.
MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335(8692):765–74.CrossRefPubMed
6.
Gorelick PB et al. Blood pressure and treatment of persons with hypertension as it relates to cognitive outcomes including executive function. J Am Soc Hypertens. 2012;6(5):309–15.CrossRefPubMed
7.
Alrawi YA et al. Pharmacological blood pressure lowering in the older hypertensive patients may lead to cognitive impairment by altering neurovascular coupling. Med Hypotheses. 2013;80(3):303–7.CrossRefPubMed
8.
Hajjar I et al. Hypertension and cerebral vasoreactivity: a continuous arterial spin labeling magnetic resonance imaging study. Hypertension. 2010;56(5):859–64.PubMedCentralCrossRefPubMed
9.
Hajjar I et al. Hypertension, white matter hyperintensities, and concurrent impairments in mobility, cognition, and mood: the cardiovascular health study. Circulation. 2011;123(8):858–65.PubMedCentralCrossRefPubMed
10.
Hofman A et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet. 1997;349(9046):151–4.CrossRefPubMed
11.
Appelman AP et al. White matter lesions and lacunar infarcts are independently and differently associated with brain atrophy: the SMART-MR study. Cerebrovasc Dis. 2010;29(1):28–35.CrossRefPubMed
12.
Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010;341:c3666.PubMedCentralCrossRefPubMed
13.
Waldstein SR et al. Pulse pressure and pulse wave velocity are related to cognitive decline in the Baltimore Longitudinal Study of Aging. Hypertension. 2008;51(1):99–104.CrossRefPubMed
14.
15.
Gustafson DR et al. The ACE insertion deletion polymorphism relates to dementia by metabolic phenotype, APOEepsilon4, and age of dementia onset. Neurobiol Aging. 2010;31(6):910–6.CrossRefPubMed
16.
17.•
Kehoe PG, Passmore PA. The renin-angiotensin system and antihypertensive drugs in Alzheimer’s disease: current standing of the angiotensin hypothesis? J Alzheimers Dis. 2012;30 Suppl 2:S251–68. A recent article reviews current evidence on effect of ACE-inhibitors and ARBs in treatment of AD.PubMed
18.
Elias MF et al. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol. 1993;138(6):353–64.PubMed
19.
Whitmer RA et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64(2):277–81.CrossRefPubMed
20.
Launer LJ et al. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA. 1995;274(23):1846–51.CrossRefPubMed
21.
Launer LJ et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21(1):49–55.CrossRefPubMed
22.
Yamada M et al. Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study. J Am Geriatr Soc. 2003;51(3):410–4.CrossRefPubMed
23.
Skoog I et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347(9009):1141–5.CrossRefPubMed
24.
Kilander L et al. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension. 1998;31(3):780–6.CrossRefPubMed
25.
26.
Nilsson SE et al. Low systolic blood pressure is associated with impaired cognitive function in the oldest old: longitudinal observations in a population-based sample 80 years and older. Aging Clin Exp Res. 2007;19(1):41–7.CrossRefPubMed
27.
Tzourio C et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163(9):1069–75.CrossRefPubMed
28.
29.
Forette F et al. The prevention of dementia with antihypertensive treatment: new evidence from the systolic hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162(18):2046–52.CrossRefPubMed
30.
No authors listed. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991; 265(24)3255–64.
31.
Lithell H et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5):875–86.CrossRefPubMed
32.
Peters R et al. Incident dementia and blood pressure lowering in the hypertension in the very elderly trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7(8):683–9.CrossRefPubMed
33.
Prince MJ et al. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council’s trial of hypertension in older adults. BMJ. 1996;312(7034):801–5.PubMedCentralCrossRefPubMed
34.
Anderson C et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2011;10(1):43–53.CrossRefPubMed
35.
McGuinness B et al. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst Rev. 2006;2:CD004034.PubMed
36.
Inaba S et al. Exaggeration of focal cerebral ischemia in transgenic mice carrying human renin and human angiotensinogen genes. Stroke. 2009;40(2):597–603.CrossRefPubMed
37.
Inaba S et al. Continuous activation of renin-angiotensin system impairs cognitive function in renin/angiotensinogen transgenic mice. Hypertension. 2009;53(2):356–62.CrossRefPubMed
38.
Yagi S et al. Renin-angiotensin-aldosterone system has a pivotal role in cognitive impairment. Hypertens Res. 2013;36(9):753–8.CrossRefPubMed
39.
Pihlaja R et al. Multiple cellular and molecular mechanisms are involved in human Aβ clearance by transplanted adult astrocytes. Glia. 2011;59(11):1643–57.CrossRefPubMed
40.
Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer’s disease? Lancet Neurol. 2007;6(4):373–8.CrossRefPubMed
41.
42.
Ciobica A et al. Brain renin-angiotensin system in cognitive function: pre-clinical findings and implications for prevention and treatment of dementia. Acta Neurol Belg. 2009;109(3):171–80.PubMed
43.
Savaskan E et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer’s dementia. Neurobiol Aging. 2001;22(4):541–6.CrossRefPubMed
44.
Starr JM, Whalley LJ, Deary IJ. The effects of antihypertensive treatment on cognitive function: results from the HOPE study. J Am Geriatr Soc. 1996;44(4):411–5.CrossRefPubMed
45.
Ohrui T et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology. 2004;63(7):1324–5.CrossRefPubMed
46.
Chrysant SG. The pathophysiologic role of the brain renin-angiotensin system in stroke protection: clinical implications. J Clin Hypertens (Greenwich). 2007;9(6):454–9.CrossRef
47.
Fournier A et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother. 2009;9(9):1413–31.CrossRefPubMed
48.
Fogari R et al. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol. 2004;59(12):863–8.CrossRefPubMed
49.
Fogari R et al. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens. 2006;20(3):177–85.CrossRefPubMed
50.
Li NC et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010;340:b5465.PubMedCentralCrossRefPubMed
51.•
Levi Marpillat N et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens. 2013;31(6):1073–82. A network meta-analysis showing class difference of antihypertensive therapies on beneficial effects on cognitive decline and prevention of dementia, with ARBs possibly being the most effective.CrossRefPubMed
52.
Ito S et al. Renin-angiotensin system in the brain as a new target of antihypertensive therapy. Hypertens Res. 2008;31(8):1487–8.CrossRefPubMed
53.
Takeda R et al. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Investig. 1995;18(5):370–3.CrossRef
54.
Yagi S et al. High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension. Hypertens Res. 2011;34(1):74–8.CrossRefPubMed
55.
Khachaturian AS et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol. 2006;63(5):686–92.CrossRefPubMed
56.
Yasar S et al. Diuretic use is associated with better learning and memory in older adults in the Ginkgo Evaluation of Memory Study. Alzheimers Dement. 2012;8(3):188–95.PubMedCentralCrossRefPubMed
57.
58.
Trompet S et al. Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study. Neurobiol Aging. 2008;29(2):306–8.CrossRefPubMed
59.
Sze KH et al. Effect of nimodipine on memory after cerebral infarction. Acta Neurol Scand. 1998;97(6):386–92.CrossRefPubMed
60.
Pantoni L et al. The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. J Neurol Sci. 2000;175(2):116–23.CrossRefPubMed
61.
Arrieta-Cruz I et al. Carvedilol reestablishes long-term potentiation in a mouse model of Alzheimer’s disease. J Alzheimers Dis. 2010;21(2):649–54.PubMed
62.
63.
Dobarro M et al. Propranolol restores cognitive deficits and improves amyloid and tau pathologies in a senescence-accelerated mouse model. Neuropharmacology. 2013;64:137–44.CrossRefPubMed
64.
Madden DJ, Blumenthal JA, Ekelund LG. Effects of beta-blockade and exercise on cardiovascular and cognitive functioning. Hypertension. 1988;11(5):470–6.CrossRefPubMed
65.
Fogari R et al. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens. 2003;17(11):781–5.CrossRefPubMed
66.•
Yasar S et al. Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology. 2013;81(10):896–903. A recent study showing antihypertensive therapies reducing risk of AD dementia independent of mean systolic blood pressure.PubMedCentralCrossRefPubMed
67.•
Gelber RP et al. Antihypertensive medication use and risk of cognitive impairment: the Honolulu-Asia Aging Study. Neurology. 2013;81(10):888–95. A recent community-based study showing beneficial effect of beta-blockers in prevention of cognitive decline in elderly >75 years.PubMedCentralCrossRefPubMed
68.
Di Bari M et al. Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial. Am J Epidemiol. 2001;153(1):72–8.CrossRefPubMed
69.•
Douiri A et al. Long-term effects of secondary prevention on cognitive function in stroke patients. Circulation. 2013;128(12):1341–8. A recent large community based study indicating post stroke preventive antihypertensive therapy and long-term reduced risk of cognitive impairment.CrossRefPubMed
70.•
Ambrosius WT et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11(5):532–46. An ongoing RCT evaluating impact of optimal blood pressure control (120 versus 140 mmHg systolic) on multiple clinical endpoints including cognitive function.CrossRefPubMed
Metadata
Title
Antihypertensive Therapies and Cognitive Function: a Review
Authors
Nisharahmed Kherada
Todd Heimowitz
Clive Rosendorff
Publication date
01-10-2015
Publisher
Springer US
Published in
Current Hypertension Reports / Issue 10/2015
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-015-0592-7

Other articles of this Issue 10/2015

Current Hypertension Reports 10/2015 Go to the issue

Hypertension and the Heart (SD Solomon and O Vardeny, Section Editors)

Influence of Physical Activity on Hypertension and Cardiac Structure and Function

Device-Based Approaches for Hypertension (M Schlaich, Section Editor)

Role of the Sympathetic Nervous System in Stress-Mediated Cardiovascular Disease

Hypertension and the Brain (S Stocker, Section Editor)

Exercise, the Brain, and Hypertension

Resistant Hypertension (E Pimenta, Section Editor)

Ambulatory Blood Pressure Monitoring in the Diagnosis, Prognosis, and Management of Resistant Hypertension: Still a Matter of our Resistance?

Guidelines/Clinical Trials/Meta-Analysis (JB Kostis, Section Editor)

Review of New Statistical Techniques for Analysis of Cardiovascular Trial and Registry Data

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits